X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20) 20
male (14) 14
female (13) 13
aged (10) 10
middle aged (9) 9
oncology (9) 9
adult (7) 7
cancer (7) 7
index medicus (7) 7
pathology (7) 7
immunohistochemistry (6) 6
adenocarcinoma (4) 4
aged, 80 and over (4) 4
carcinoma (4) 4
carcinoma, renal cell - drug therapy (4) 4
immunology (4) 4
kidney neoplasms - drug therapy (4) 4
neoplasms (4) 4
pancreatic neoplasms - pathology (4) 4
retrospective studies (4) 4
tumors (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
apelin (3) 3
bile duct carcinoma (3) 3
bile duct neoplasms - pathology (3) 3
bile duct stenosis (3) 3
biomarkers, tumor - analysis (3) 3
brush cytology (3) 3
care and treatment (3) 3
clear cell-type renal cell carcinoma (3) 3
cyclophosphamide (3) 3
dna, neoplasm - analysis (3) 3
dosage and administration (3) 3
ercp (3) 3
everolimus (3) 3
immunoregulation (3) 3
loss of heterozygosity (3) 3
lymphocytes t (3) 3
medicine & public health (3) 3
metastases (3) 3
metastasis (3) 3
microsatellite repeats (3) 3
mtor (3) 3
mutations (3) 3
neoplasm metastasis (3) 3
p53 immunocytochemistry (3) 3
pancreatic cancer (3) 3
smad4 protein (3) 3
t cells (3) 3
tor protein (3) 3
treatment outcome (3) 3
tregs (3) 3
adenocarcinoma - chemistry (2) 2
adenocarcinoma - pathology (2) 2
adiponectin (2) 2
adiponectin - blood (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
antitumor activity (2) 2
bile duct neoplasms - metabolism (2) 2
bile ducts, extrahepatic - pathology (2) 2
cancer research (2) 2
carcinoma, renal cell - mortality (2) 2
carcinoma, renal cell - pathology (2) 2
cell survival (2) 2
child (2) 2
clinical trials (2) 2
disease progression (2) 2
dna-binding proteins - analysis (2) 2
drug administration schedule (2) 2
efficacy (2) 2
endothelial growth-factor (2) 2
everolimus - administration & dosage (2) 2
everolimus - adverse effects (2) 2
expression (2) 2
follow-up studies (2) 2
gene (2) 2
genes, ras - genetics (2) 2
ifosfamide (2) 2
insulin-resistance (2) 2
intercellular signaling peptides and proteins - blood (2) 2
k-ras (2) 2
kaplan-meier estimate (2) 2
kidney neoplasms - mortality (2) 2
kidney neoplasms - pathology (2) 2
lesions (2) 2
liver (2) 2
medical research (2) 2
medicine, experimental (2) 2
mrcc (2) 2
neoplasm proteins - analysis (2) 2
original (2) 2
p53 (2) 2
pancreas (2) 2
pancreatic neoplasms - genetics (2) 2
pancreaticoduodenectomy (2) 2
patients (2) 2
pharmacology (2) 2
ras codon-12 mutations (2) 2
regular (2) 2
regular articles (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Immunology Immunotherapy, ISSN 0340-7004, 2019, Volume 68, Issue 3, pp. 503 - 515
Journal Article
Cancer Immunology Immunotherapy, ISSN 0340-7004, 2019, Volume 68, Issue 2, pp. 319 - 329
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and... 
mTOR | Cyclophosphamide | Everolimus | Tregs | IMMUNOLOGY | CANCER | TRIAL | LENVATINIB | THERAPY | ONCOLOGY | IMMUNE SUPPRESSION | REGULATORY T-CELLS | TYROSINE KINASE INHIBITOR | MODULATION | ENDOTHELIAL GROWTH-FACTOR | Cyclophosphamide - administration & dosage | Administration, Oral | Carcinoma, Renal Cell - pathology | Humans | Middle Aged | Kaplan-Meier Estimate | Anemia - chemically induced | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Everolimus - administration & dosage | Fatigue - chemically induced | Cyclophosphamide - adverse effects | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Everolimus - adverse effects | Adult | Anorexia - chemically induced | Female | Kidney Neoplasms - pathology | Aged | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - drug therapy | Cohort Studies | Complications and side effects | Medical research | Care and treatment | Analysis | Clinical trials | Medicine, Experimental | Dosage and administration | Metastasis | T cells | Cancer | TOR protein | Cell survival | Immune response | Immunoregulation | Toxicity | Fatigue | Lymphocytes T | Patients | Metastases | Angiogenesis | Immunosuppression | Pneumonitis | Antitumor activity | Clear cell-type renal cell carcinoma | Index Medicus | Clinical Trial Report
Journal Article
Cancer immunology, immunotherapy, ISSN 0340-7004, 05/2019, Volume 68, Issue 5, pp. 787 - 798
Introduction: Metastatic renal cell cancer (mRCC) patients have a median overall survival (mOS) of approximately 28 months. Until recently, mammalian target of... 
Cyclophosphamide/therapeutic use | Kidney Neoplasms/drug therapy | Cell Proliferation | Follow-Up Studies | Everolimus/therapeutic use | Humans | Middle Aged | T-Lymphocytes, Regulatory/immunology | Male | Treatment Outcome | Survival Analysis | Carcinoma, Renal Cell/drug therapy | Female | Aged | Immunosuppressive Agents/therapeutic use | TOR Serine-Threonine Kinases/metabolism | Cyclophosphamide | Immunology | Medicine & Public Health | Tregs | mRCC | mTOR | Oncology | Cancer Research | Everolimus | MIGRATION | SURVIVAL | EFFICACY | EAU GUIDELINES | IMMUNOLOGY | TRIAL | INTERFERON-ALPHA | ONCOLOGY | SUNITINIB | CARCINOMA | TOR Serine-Threonine Kinases - metabolism | Immunosuppressive Agents - therapeutic use | Kidney Neoplasms - mortality | Cyclophosphamide - therapeutic use | T-Lymphocytes, Regulatory - immunology | Carcinoma, Renal Cell - mortality | Everolimus - therapeutic use | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - drug therapy | Tyrosine | Medical research | Care and treatment | Endothelial growth factors | Patient outcomes | Medicine, Experimental | Metastasis | T cells | Cancer | TOR protein | Cell survival | Immunoregulation | Lymphocytes T | Rapamycin | Patients | Metastases | Kidney cancer | Protein-tyrosine kinase receptors | Antitumor activity | Vascular endothelial growth factor | Protein-tyrosine kinase | Clear cell-type renal cell carcinoma
Journal Article
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 2019, Volume 68, Issue 3, pp. 503 - 515
For the treatment of metastatic renal cell cancer several strategies are used among which the mTOR inhibitor everolimus. As mTOR plays an important role in the... 
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 2019
Introduction: Metastatic renal cell cancer (mRCC) patients have a median overall survival (mOS) of approximately 28 months. Until recently, mammalian target of... 
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 11/2018
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and... 
b_open_article_in_toll_access_journal
Journal Article
The Oncologist, ISSN 1083-7159, 07/2006, Volume 11, Issue 7, pp. 732 - 741
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue Suppl_15, pp. 4572 - 4572
Journal Article
Nederlands Tijdschrift voor Geneeskunde, ISSN 0028-2162, 2014, Issue 25, pp. 454 - 460
Journal Article
Nederlands tijdschrift voor geneeskunde, ISSN 0028-2162, 2014, Volume 158, p. A7354
Journal Article
The Journal of Molecular Diagnostics, ISSN 1525-1578, 05/2018, Volume 20, Issue 3, pp. 316 - 325
Recent reports have emphasized the clinical relevance of detecting in circulating tumor cells (CTCs). Our aim was to set up a validated multicenter pipeline to... 
PATHOLOGY | RESISTANT PROSTATE-CANCER | MEN | ENZALUTAMIDE | ABIRATERONE
Journal Article
Nederlands tijdschrift voor geneeskunde, 2014, Volume 158, p. A7354
Journal Article
Journal Article
American Journal of Pathology, ISSN 0002-9440, 05/2000, Volume 156, Issue 5, pp. 1641 - 1651
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.